To the Editor.—

We read with interest the article written by Spencer et al. The authors concluded that atomoxetine doesn't have an unfavorable effect on growth in pediatric patients. However, some doubts arise about the methods used to support this assertion: height was measured sporadically across several studies of the clinical development program for atomoxetine in which the duration of exposure varied from 3 months to >2 years. The main criterion was based on the change in height from baseline to the end point and compared to predicted normative values. The analysis was performed according to the baseline quartile and the age of the patient at the first atomoxetine dose. The mean patient age at enrollment was 10.6 years; among them, ∼70% were ≤12 years old. Most of them, therefore, were presumably in pubertal development. Because during this period the height speed increases very fast, it would have...

You do not currently have access to this content.